Day One Biopharmaceuticals, Inc. (DAWN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 13.53 |
| Open | 13.53 |
| Bid | 13.38 x 100 |
| Ask | 13.43 x 100 |
| Day's Range | 13.39 - 14.01 |
| 52 Week Range | 9.67 - 18.07 |
| Volume | |
| Avg. Volume | 1,148,951 |
| Market Cap | 1.171B |
| Beta (5Y Monthly) | -1.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.50 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.63 |
WWDLupita Nyong’o Gives Power Suiting a Sensual Spin in Double-breasted Blazer and High-waisted Shorts for ‘A Quiet Place: Day One’ Photo Call
The Oscar-winning actress was joined by costars Djimon Hounsou, Joseph Quinn and Alex Wolff on Monday.
GuruFocus.comInsider Selling: Director Saira Ramasastry Sells Shares of Day One Biopharmaceuticals Inc (DAWN)
Director Saira Ramasastry sold 10,000 shares of Day One Biopharmaceuticals Inc (NASDAQ:DAWN) on June 21, 2024, as reported in a recent SEC Filing.
GlobeNewswireDay One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024 Targets PTK7, highly expressed in broad range of adult and pediatric solid tumors BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threat
© 2024 Yahoo. All rights reserved.